Evidence map›Paper›PMID 35441793›Full record

ReviewJournal of thrombosis and haemostasis : JTH2022

Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer.

Cian Desai, Milka Koupenova, Kellie R Machlus, Anirban Sen Gupta

Abstract readReview
In one paragraph

Review in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Toward targeting of inflammasome signaling in venous thrombosis.Journal of thrombosis and haemostasis : JTH · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cian DesaiDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0001-9290-5015
Milka KoupenovaDivision of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.ORCID 0000-0001-5934-8990
Kellie R MachlusDepartment of Surgery, Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-2155-1050
Anirban Sen GuptaDepartment of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-5773-0667

Funding

University of Massachusetts Center for Clinical Science and Translational SupplementUL1TR001453 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUZURIAGA, KATHERINE F · 2015 to 2024
$39.0M
PREDOCTORAL TRAINING PROGRAM IN MOLECULAR THERAPEUTICST32GM008803 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI MIEYAL, JOHN J, NIEMAN, MARVIN THOMAS · 2001 to 2023
$4.2M
Heteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet AnaloguesR01HL121212 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SEN GUPTA, ANIRBAN · 2014 to 2024
$4.1M
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1M
The Biogenesis of Platelet-Derived Extracellular Vesicles and their Impact on Megakaryocyte MaturationR01HL151494 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI MACHLUS, KELLIE RAE · 2021 to 2025
$2.9M
Mechanisms of platelet reprogramming during influenza infectionR01HL153235 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KOUPENOVA, MILKA · 2020 to 2024
$2.1M
Targeted Abrogation of the FXII-uPAR-pAkt2 Axis in Neutrophils for Treatment of Chronic WoundsR01HL137695 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI STAVROU, EVI X. · 2019 to 2023
$2.0M
Elucidation of the mechanisms by which fatty acids drive megakaryopoiesisR01DK139341 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Kellie Rae Machlus · 2024 to 2026
$1.1M
The Role of CCL5 in Hematopoietic Stem Cell Activation and SkewingR03DK124746 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI MACHLUS, KELLIE RAE · 2021 to 2022
$266k
NCATS NIH HHS UL1 TR001453NHLBI NIH HHS R01 HL121212NHLBI NIH HHS R01 HL137695NHLBI NIH HHS R01 HL141080NHLBI NIH HHS R01 HL151494NHLBI NIH HHS R01 HL153235NIDDK NIH HHS R01 DK139341NIDDK NIH HHS R03 DK124746NIGMS NIH HHS T32 GM008803
6 · The paper itself

Abstract

The traditional role of platelets is in the formation of blood clots for physiologic (e.g., in hemostasis) or pathologic (e.g., in thrombosis) functions. The cellular and subcellular mechanisms and signaling in platelets involved in these functions have been extensively elucidated and new knowledge continues to emerge, resulting in various therapeutic developments in this area for the management of hemorrhagic or thrombotic events. Nanomedicine, a field involving design of nanoparticles with unique biointeractive surface modifications and payload encapsulation for disease-targeted drug delivery, has become an important component of such therapeutic development. Beyond their traditional role in blood clotting, platelets have been implicated to play crucial mechanistic roles in other diseases including inflammation, immune response, and cancer, via direct cellular interactions, as well as secretion of soluble factors that aid in the disease microenvironment. To date, the development of nanomedicine systems that leverage these broader roles of platelets has been limited. Additionally, another exciting area of research that has emerged in recent years is that of platelet-derived extracellular vesicles (PEVs) that can directly and indirectly influence physiological and pathological processes. This makes PEVs a unique paradigm for platelet-inspired therapeutic design. This review aims to provide mechanistic insight into the involvement of platelets and PEVs beyond hemostasis and thrombosis, and to discuss the current state of the art in the development of platelet-inspired therapeutic technologies in these areas, with an emphasis on future opportunities.

Indexed as

NeoplasmsThrombosisBlood PlateletsHumansImmunityInflammationNanomedicineTumor Microenvironmentcancerextracellular vesiclesimmune responseinflammationnanomedicineplatelets

Identifiers

PMID35441793
PMCPMC9321119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.